ParkinsonFranceV1, Main, Exploration, bibRecord, 003B67

Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion

Identifieur interne : 003B67 ( Main/Exploration ); précédent : 003B66; suivant : 003B68

Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion

Auteurs : E. C. Hirsch [France] ; BENABID ; OLANOW ; SEALFON ; HALLETT ; LANGSTON ; CALABRESI

Source :

Annals of neurology [ 0364-5134 ] ; 2000.

RBID : Pascal:00-0262933

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Lévodopa, Antiparkinsonien, Voie nigrostriatale, Plasticité synaptique, Article synthèse, Physiopathologie, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Corpus Striatum (drug effects), Corpus Striatum (physiopathology), Dopamine (physiology), Dopamine Agents (adverse effects), Dyskinesia, Dyskinesia, Drug-Induced (physiopathology), Human, Humans, Levodopa, Levodopa (adverse effects), Nerve Degeneration (chemically induced), Nerve Degeneration (physiopathology), Neuronal Plasticity (drug effects), Nigrostriatal pathway, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Pathophysiology, Review, Substantia Nigra (drug effects), Substantia Nigra (physiopathology), Synaptic plasticity.
MESH :
- chemical , adverse effects : Dopamine Agents, Levodopa.
- chemical , physiology : Dopamine.
- chemically induced : Nerve Degeneration.
- drug effects : Corpus Striatum, Neuronal Plasticity, Substantia Nigra.
- drug therapy : Parkinson Disease.
- physiopathology : Corpus Striatum, Dyskinesia, Drug-Induced, Nerve Degeneration, Parkinson Disease, Substantia Nigra.
- Humans.

Abstract

Clinical studies suggest that the appearance of levodopa-induced dyskinesias may be partly related to changes in the dopaminergic system. This article reviews data on biochemical and morphological changes induced by treatment, the lesion, or both, in dopaminergic neurons themselves, postsynaptic striatal tissue, and afferent fibers to dopaminergic neurons in the substantia nigra. Recent studies on dopaminergic neurons suggest that levodopa therapy can induce sprouting of surviving dopaminergic neurons at their terminals in the striatum. At the postsynaptic level, treatment may trigger induction of D3 dopamine receptors and internalization of D1 receptors. Furthermore, dopaminergic denervation has been shown to be involved in plastic changes in the striatum associated with hyperactivity of glutamatergic fibers making synapses with the head of the spines of γ-aminobutyric acid-ergic neurons. At the level of the dendrites of dopaminergic neurons, plasticity of excitatory cholinergic afferent fibers targeting dopaminergic neurons and an involution of noncholinergic afferent fibers have been observed. Taken together, these data suggest that dopaminergic denervation and treatment induce profound plastic changes in the nigrostriatal system. Whether such changes participate in side-effects of treatment and, in particular, the appearance of dyskinesias remains to be determined.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion</title>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U 289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benabid" sort="Benabid" uniqKey="Benabid" last="Benabid">BENABID</name>
</author>
<author><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">OLANOW</name>
</author>
<author><name sortKey="Sealfon" sort="Sealfon" uniqKey="Sealfon" last="Sealfon">SEALFON</name>
</author>
<author><name sortKey="Hallett" sort="Hallett" uniqKey="Hallett" last="Hallett">HALLETT</name>
</author>
<author><name sortKey="Langston" sort="Langston" uniqKey="Langston" last="Langston">LANGSTON</name>
</author>
<author><name sortKey="Calabresi" sort="Calabresi" uniqKey="Calabresi" last="Calabresi">CALABRESI</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0262933</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0262933 INIST</idno>
<idno type="RBID">Pascal:00-0262933</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001386</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000052</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001189</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001189</idno>
<idno type="wicri:doubleKey">0364-5134:2000:Hirsch E:nigrostriatal:system:plasticity</idno>
<idno type="wicri:Area/Main/Merge">004226</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10762138</idno>
<idno type="wicri:Area/PubMed/Corpus">001327</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001327</idno>
<idno type="wicri:Area/PubMed/Curation">001286</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001286</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001286</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001286</idno>
<idno type="wicri:Area/Ncbi/Merge">000103</idno>
<idno type="wicri:Area/Ncbi/Curation">000103</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000103</idno>
<idno type="wicri:doubleKey">0364-5134:2000:Hirsch E:nigrostriatal:system:plasticity</idno>
<idno type="wicri:Area/Main/Merge">003E90</idno>
<idno type="wicri:Area/Main/Curation">003B67</idno>
<idno type="wicri:Area/Main/Exploration">003B67</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion</title>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U 289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benabid" sort="Benabid" uniqKey="Benabid" last="Benabid">BENABID</name>
</author>
<author><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">OLANOW</name>
</author>
<author><name sortKey="Sealfon" sort="Sealfon" uniqKey="Sealfon" last="Sealfon">SEALFON</name>
</author>
<author><name sortKey="Hallett" sort="Hallett" uniqKey="Hallett" last="Hallett">HALLETT</name>
</author>
<author><name sortKey="Langston" sort="Langston" uniqKey="Langston" last="Langston">LANGSTON</name>
</author>
<author><name sortKey="Calabresi" sort="Calabresi" uniqKey="Calabresi" last="Calabresi">CALABRESI</name>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Corpus Striatum (drug effects)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Dopamine (physiology)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Nerve Degeneration (chemically induced)</term>
<term>Nerve Degeneration (physiopathology)</term>
<term>Neuronal Plasticity (drug effects)</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Pathophysiology</term>
<term>Review</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Synaptic plasticity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Nerve Degeneration</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term>
<term>Neuronal Plasticity</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Voie nigrostriatale</term>
<term>Plasticité synaptique</term>
<term>Article synthèse</term>
<term>Physiopathologie</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Clinical studies suggest that the appearance of levodopa-induced dyskinesias may be partly related to changes in the dopaminergic system. This article reviews data on biochemical and morphological changes induced by treatment, the lesion, or both, in dopaminergic neurons themselves, postsynaptic striatal tissue, and afferent fibers to dopaminergic neurons in the substantia nigra. Recent studies on dopaminergic neurons suggest that levodopa therapy can induce sprouting of surviving dopaminergic neurons at their terminals in the striatum. At the postsynaptic level, treatment may trigger induction of D3 dopamine receptors and internalization of D1 receptors. Furthermore, dopaminergic denervation has been shown to be involved in plastic changes in the striatum associated with hyperactivity of glutamatergic fibers making synapses with the head of the spines of γ-aminobutyric acid-ergic neurons. At the level of the dendrites of dopaminergic neurons, plasticity of excitatory cholinergic afferent fibers targeting dopaminergic neurons and an involution of noncholinergic afferent fibers have been observed. Taken together, these data suggest that dopaminergic denervation and treatment induce profound plastic changes in the nigrostriatal system. Whether such changes participate in side-effects of treatment and, in particular, the appearance of dyskinesias remains to be determined.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Benabid" sort="Benabid" uniqKey="Benabid" last="Benabid">BENABID</name>
<name sortKey="Calabresi" sort="Calabresi" uniqKey="Calabresi" last="Calabresi">CALABRESI</name>
<name sortKey="Hallett" sort="Hallett" uniqKey="Hallett" last="Hallett">HALLETT</name>
<name sortKey="Langston" sort="Langston" uniqKey="Langston" last="Langston">LANGSTON</name>
<name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">OLANOW</name>
<name sortKey="Sealfon" sort="Sealfon" uniqKey="Sealfon" last="Sealfon">SEALFON</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B67 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B67 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:00-0262933
   |texte=   Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion

Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.